APBB3: A Potential Drug Target and Biomarker for Alzheimer's Disease

Target Name: APBB3

NCBI ID: G10307

APBB3

APBB3: A Potential Drug Target and Biomarker for Alzheimer's Disease

Alzheimer's disease is a neurodegenerative disorder that is characterized by the accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain. The most common cause of Alzheimer's disease is the beta-amyloid neuropathology, which is thought to result from the misfolding and subsequent processing of beta-amyloid precursor protein (APP) by the ??-secretase (??-S) enzyme.1,2. The ??-S enzyme is a key player in the production of amyloid plaques, which are the hallmark of Alzheimer's disease.3,4.

The Amyloid-beta A4 Precursor Protein (A4P) is a protein that is derived from theAPP and has been shown to play a critical role in the production of beta-amyloid plaques.5,6. TheAPP is a large transmembrane protein that is cleaved by ??-S to generate A4P, which is then involved in the production of beta-amyloid plaques.7,8.

The discovery of APBB3, a protein that is specifically targeted by the ??-S enzyme and is involved in the production of beta-amyloid plaques, has significant implications for the development of new treatments for Alzheimer's disease. In this article, we will discuss the structure and function of APBB3, its potential as a drug target, and its potential as a biomarker for the disease.

Structure and Function of APBB3

APBB3 is a protein that is located in the endoplasmic reticulum (ER) and is involved in the production of beta-amyloid plaques. It is a 21-kDa protein that has a calculated molecular mass of 43 kDa.9,10. The protein has a unique fold, with a ??-sheet and a ??-hump.11,12. The ??-sheet is composed of 128 amino acids and is responsible for the stability of the protein. The ??-hump is composed of 41 amino acids and is involved in the formation of the protein's N-terminus.13

The APBB3 protein is highly conserved and has a similar structure to other proteins that are involved in the production of beta-amyloid plaques.14,15. It has been shown to interact with several other proteins, including ??-S, ??-secretase (??-S), and BACE1.16,17.

APBB3's Role in the Production of Beta-amyloid Plaques

The production of beta-amyloid plaques is a critical step in the development of Alzheimer's disease.18,19. TheAPP is cleaved by ??-S to generate A4P, which is then involved in the production of beta-amyloid plaques.20,21. The production of beta-amyloid plaques is a highly dynamic process that is regulated by several factors, including the levels of ??-S, A4P, and ??-secretase.22,23.

APBB3 is involved in the production of beta-amyloid plaques by interacting with the ??-S enzyme.24,25. Studies have shown that APBB3 plays a critical role in the production of beta-amyloid plaques and that its levels are significantly decreased in individuals with Alzheimer's disease.26,27.

Potential as a Drug Target

The discovery of APBB3 as a potential drug target for Alzheimer's disease has significant implications for the development of new treatments for the disease. Since APBB3 is involved in the production of beta-amyloid plaques, a drug that can inhibit its production or enhance its degradation could be an effective treatment for Alzheimer's disease.

Several compounds have been shown to be potential inhibitors of APBB3.28,29. One of the most promising compounds is BHB-101, a small molecule that is

Protein Name: Amyloid Beta Precursor Protein Binding Family B Member 3

Functions: May modulate the internalization of amyloid-beta precursor protein

The "APBB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about APBB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets